ScripChina’s retaliatory tariffs mean the option of manufacturing US-originated drugs in China is making more sense than ever, at least to some local partners of US pharmaceutical companies. China imposed
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Merck Obtains Global Rights To Hansoh’
ScripThe sustainable supply of drugs for antimicrobial resistance (AMR) is needed on a global scale. However, this will require both pull incentive models for reimbursement and high technology for producin
ScripAmid an ongoing capital crunch, Chinese drug makers pursuing in-licensing models have arrived at a commercialization crossroads. Jump-started by frontrunner Zai Lab Ltd. ’s successful introduction of